In order to help prepare for the annual meeting of the American Society of Clinical Oncology, better known as ASCO, I've compiled a cheat sheet of significant cancer research abstracts.

Use these abstract numbers and titles to search the ASCO Web site on May 15, starting at 9 p.m. EDT. That's when the cancer research group will be posting the full content of the annual meeting research abstracts online.

This is the first time ASCO has made research abstracts freely available to everyone in advance of its annual meeting, which runs May 31 through June 3. In years past, of course, many of these abstracts, often containing important and potentially market-moving clinical data, have leaked to well-connected Wall Street investors and traders.

That has led to volatile trading in cancer-related biotech stocks in advance of the ASCO meeting. Whether trading volatility ramps up or down this year with abstracts available to everyone remains to be seen. With the list I've put together, however, you should be ready.

Before we get to the list of significant abstracts, here are a few notes:

The ASCO Web site can be found at www.asco.org, where the annual meeting abstracts will be made available in the Annual Meeting Program Online.

As I've warned in the past, ASCO is keeping abstracts for plenary sessions and certain late-breaking presentations under wraps until the start of the meeting. Most importantly, this means that Erbitux results from the FLEX lung cancer study will not be available on May 15. That means ImClone Systems ( IMCL) investors will just have to wait a little while longer.

I spent a couple of days culling through the thousands of ASCO abstract titles, looking for those that seemed the most significant to biotech and drug investors. However, this doesn't necessarily mean that there will be a lot of market-moving data, if any, in the actual abstracts when they're posted online May 15.

Sometimes, abstracts can be chock-full of clinical data that don't change much once the meeting gets under way and the final data are presented. In other instances, the abstracts are more placeholders, with little relevant information.

Therefore, I hope you'll use this list more as a guide to what might be potentially important information coming out of the ASCO meeting. And if shares of a certain cancer-related biotech stock move wildly up or down on May 16, you'll be able to check it against this list to see if the volatility is ASCO-related.

Without further delay, here is my list of notable ASCO research abstracts, in alphabetical order by company name.


Amgen ( AMGN - Get Report):

Abstract No. 2051: Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme.


Ariad Pharmaceuticals ( ARIA):

Abstract No. 3509: Deforolimus trial 106-A phase I trial evaluating seven regimens of oral Deforolimus (AP23573, MK-8669).


Arqule ( ARQL):

Abstract No. 3584: Phase I trial to determine the dose range for the c-Met inhibitor ARQ 197 that inhibits c-Met and FAK phosphorylation, when administered by an oral, twice-a-day schedule.


Array BioPharma ( ARRY):

Abstract No. 4114: AZD6244 (ARRY-142886) vs. capecitabine in patients with metastatic colorectal cancer who have failed prior chemotherapy.

Abstract No. 9033: AZD6244 (ARRY-142886) vs. temozolomide in patients with advanced melanoma; an open-label, randomized, multicenter, phase II study.

Abstract No. 8029: Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients with advanced non-small-cell lung cancer.


Avant Immunotherapeutics

Abstract No. 2011: Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM.


Celgene ( CELG - Get Report):

Abstract No. 8509: International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin's lymphoma.

Abstract No. 8504: Randomized trial of lenalidomide plus high-dose dexamethasone vs. lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group; Analysis of response and survival.


Cell Genesys :

Abstract No. 5146: Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC).


Cougar Biotechnology :

Abstract No. 5019: Abiraterone acetate and prednisone in patients with progressive metastatic castration resistant prostate cancer after failure of docetaxel-based chemotherapy.

Abstract No. 5005: Anti-tumor activity of abiraterone acetate (AA), a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer.


Curis ( CRIS):

Abstract No. 3516: A first-in-human, first-in-class, phase I study of systemic Hedgehog pathway antagonist, GDC-0449, in patients with advanced solid tumors.


Eli Lilly ( LLY - Get Report):

Abstract No. 8011: Maintenance pemetrexed plus best supportive care vs. placebo plus BSC: A phase III study. Lung cancer.


Exelixis ( EXEL):

Abstract No. 3522: A phase I study of XL184, a RET, VEGFR2 and MET kinase inhibitor, in patients with advanced malignancies, including patients with medullary thyroid cancer.

Abstract No.8028: Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial.

Abstract No. 5103: A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients with papillary renal carcinoma.

Abstract No. 3510: A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients with advanced solid tumors.


Genentech :

Abstract No. LBA1011: Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer: AVADO.

Abstract No. 2010b: A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on six-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM).

Abstract No. 4006: Initial safety report of NSABP C-08, a randomized phase III study of modified 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab in the adjuvant treatment of patients with stage II/III colon cancer.

Abstract No. 8511: A phase I study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies.

Abstract No 5520: A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab vs. carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer.

Abstract No. 1026: Results of a phase II trial of trastuzumab and pertuzumab in patients with HER2-positive metastatic breast cancer who had progressed during trastuzumab therapy.


Genvec ( GNVC):

Abstract No. 6067: A phase I dose escalation study of Ad GV.EGR.TNF.11D with concurrent chemoradiotherapy in patients with recurrent head and neck cancer.


ImClone Systems:

Abstract No. 3: FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) vs. CV alone in the first-line treatment of patients with advanced non-small-cell lung cancer. (Note: Will not be available online May 15.)

Abstract No. LBA4011: Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group.

Abstract No. 2: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. (Note: Will not be available online May 15.)


Immunogen ( IMGN):

Abstract No. 1028: A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2+ breast cancer.


Incyte ( INCY):

Abstract No. 7004: A phase I/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF).


Medarex :

Abstract No. 9010: Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma.

Abstract No. 3018: Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10 mg/kg every three weeks for four doses (induction dosing).

Abstract No. 9025: Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study.


Medivation ( MDVN):

Abstract No. 5006: Phase I/II study of MDV3100 in patients with progressive castration-resistant prostate cancer.


Onyx Pharmaceuticals ( ONXX):

Abstract No. 4509: Randomized phase III trial of sorafenib vs. placebo in Asian patients with advanced hepatocellular carcinoma.

Abstract No. 6527: Economic evaluation of sorafenib vs. best supportive care in hepatocellular carcinoma.

OSI Pharmaceuticals :

Abstract No. 4507: A randomized, double-blind, placebo controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab to erlotinib and gemcitabine in patients with metastatic pancreatic cancer. (Note: This study previously announced failed.)


PDL BioPharma ( PDLI) and Biogen Idec ( BIIB):

Abstract No. 9051: A multicenter phase II study of volociximab in patients with relapsed metastatic melanoma.


Pfizer ( PFE - Get Report):

Abstract No. 4521: Sunitinib monotherapy in patients with advanced hepatocellular carcinoma; insights from a multidisciplinary phase II study.

Abstract No. 8015: High activity of the anti-IGF-IR antibody CP-751,871 in combination with paclitaxel and carboplatin in squamous NSCLC.

Abstract No. 9006: Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study.

Poniard Pharmaceuticals ( PARD):

Abstract No. 5153: A phase II study of picoplatin with docetaxel and prednisone in chemotherapy-naïve patients with metastatic hormone refractory prostate cancer.


Regeneron Pharmaceuticals ( REGN):

Abstract No. 4027: Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer: A PMH phase II consortium trial.


Seattle Genetics ( SGEN):

Abstract No. 8526: Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma.


SuperGen :

Abstract No. 7032: A multicenter phase II trial of the decitabine alternative five-day dosing regimen; analysis of efficacy in various subgroups of patients with myelodysplastic syndromes.


Synta Pharmaceuticals ( SNTA):

Abstract No. 9036: Phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM): Subgroup analysis by prior chemotherapy.

Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.